Main Article Content

Abstract

Background

Hypertension is one of the most common non-communicable disease. There are a number factors, presently prevalent in our daily life that are increasing the prevalence of hypertension in nearly all age groups, but more as age increases. Beta receptor antagonists are one of the groups of drugs used in all grades of hypertension. Ca2+ channel blockers are the other class of antihypertensive agents, used in different situations of hypertension. But many times, single drug therapy is not sufficient to maintain normal blood pressure. And combination therapy has its own problems like increase side effects, cost etc. Hence, present study is undertaken to determine the difference between efficacy and tolerability of atenolol and combination of amolodopine and atenolol.


Objectives

To compare the efficacy and tolerability of atenolol and combination of amolodopine and atenolol in maintaining normal blood pressure.


Materials and methods

A total of hundred patients were taken for the study. Fifty patients are given atenolol and other fifty are given combination of amolodopine and atenolol, once a day, daily for one month. Blood pressure of all the patients is recorded daily in laying position for one month. Data collected was analyzed statistically using descriptive statistics. Any adverse effects, symptoms of hypertension and patient compliance is also noted in the follow up visits.


Results

Blood pressure levels were maintained at normal limits, more in combination therapy compared to atenolol alone therapy. Blood pressure variations were also less with combination therapy. Side effects were somewhat more in the combination therapy. Patient compliance was good.


Interpretation and conclusion

Combination of amolodipine and atenolol seems to be more effective in the treatment of hypertension in comparison to atenolol alone.

Keywords

Atenolol Amolodopine Hypertension

Article Details

How to Cite
Dr.Wasif S, & Dr.Mohsin. (2021). An observative study of comparison of efficacy and tolerability between atenolol and combination of amolodopine with atenolol in the maintence therapy of hypertension in a tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(4), 413-420. https://doi.org/10.61096/ijrpp.v6.iss4.2017.413-420

References

  1. [1]. Katzung, B.G., Masters, S.B., and Trevor, A.J. Basic and Clinical Pharmacology. New York: McGraw-Hill Medical 3, 2015.
  2. [2]. Del Mauro JS, et al. Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. J AMSocHypertens. 1(4), 2017, 227-240.
  3. [3]. Ahlquist D, Camilleri M editors. Cardiovascular Diseases. In: Harrisons: Principles of internal medicine. 19th Ed. McGraw Hill companies:2016, 241-250.
  4. [4]. Brunton LL, Chabner BA, Knollmann BC, editors. Treatment of Myocardial ischeamiaand Hypertension. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13thEd. New York: McGraw-Hill Companies; 2017.
  5. [5]. Whelton, P.K., et al. J Am CollCardiol. 10.1016/j.jacc.2017.11.006.
  6. [6]. Kuyper LM, Khan NA. Atenolol vsnonatenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol. 30(5), 2014, S47-53.
  7. [7]. McGill JB. Optimal use of beta blockers in high-risk hypertension: a guide to dosing equivalence. Vasc Health Risk Manag. 6, 2010, 363-72.
  8. [8]. Oparil S, et al. Long term morbidity and mortality trials with amlodipine. Journal of Cardiovascular Pharmacology: 33, 1999, S1-S6.
  9. [9]. Carlberg B, Samuelson O, Lindholm LH. Atenolol in hypertension: is it a wise choice?. The Lancet. 365(9460), 2005, 656.
  10. [10]. Aursnes I, Tvete IF, et al. Clinical efficacies of antihypertensive drugs. Scandinavian Cardiovascular Journal.37, 2003, 2.
  11. [11]. Morgan TO, Anderson AI, Maclnnis RJ. ACE inhibitors, beta blockers, calcium channel blockers and diuretics for the control of systolic hypertension. American journal of hypertension. 14(3), 2001, 241-247.
  12. [12]. Frishman WH, et,al. Amolodipine versus atenolol in essential hypertension. The American Journal of Cardiology.73(3), 1994, A50-A54.
  13. [13]. Ling G, et al. Effects of combination therapy with at Enolol and amlodipine on blood pressure control and stroke prevention in stroke –prone spontaneously hypertensive rats. ActaPharmacol Sin. 28(11), 2007, 1755-60.
  14. [14]. Wald. D.S, et. al. Combination therapy versus monotherapy in reducing blood pressure : Meta-analysis on 11,000 participants from 42 trials. The American Journal of Medicine. 122(3), 2009, 290-300.
  15. [15]. Han P, et al. The combination of atenolol and amlodipine is better than their monotherapy for preventing end- organ damage in different types of hypertension in rats. J Cell Mol Med. 13(4), 2009, 726-34.
  16. [16]. Wang JG, et al. Predictors of visit-to-visit bood pressure variability in patients with hypertension: an analysis of trials with an amolodipine treatment arm. J AMSocHypertens. 11(7), 2017, 402-411.
  17. [17]. Bangalore S, Sawhney S, Messerli FH. Relation of Beta-Blocker induced Heart rate lowering and cardioprotection in Hypertension. Journal of the American College of Cardiology. 52(18), 2008.
  18. [18]. Kostis JB. Visit-to-visit variability of blood pressure. J AMSocHypertens. 11(8), 2017, 473-474.
  19. [19]. Ibrahim MM, Mossallam R. Clinical evaluation of atenolol in hypertensive patients. Circulation. 64(2), 1981, 368-74.
  20. [20]. Tripati KD. Antihypertensive Drugs. In. Essentials of Medical Pharmacology. Jaypeebrothers medical publishers. 7, 2011.
  21. [21]. Wright JM, Musuni VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 3, 2009.
  22. [22]. Wang JG, et al. Effects of amolodipine and other classes of antihypertensive drugs on long term blood pressure variability: evidence from randomized controlled trials. J AMSocHypertens. 8(5), 2014, 340-9.
  23. [23]. Rothwell PM, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 9(5), 2010, 469-80.
  24. [24]. Wong GW, et al. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane DtabaseSyst Rev. 3, 2016. :CD007451.
  25. [25]. Barrett J, Rahul B ,Jeffery R. incremental blood pressure- lowering effect of titrating amolodipine for the treatment of hypertension in patients including those aged ≥ 55 years. American journal of therapeutics. 22(4), 2015, 278-287.
  26. [26]. Kasture A.V, Ramteke M. Simultaneous UV- spectrophotometric method for the estimation of atenolol and amlodipine besylate in combined dosage form. Indaian J Pharm Sci. 68(3), 2006, 394-396.
  27. [27]. Barrett J, Jeffery R, Rahul B. Efficacy of calcium channel blockers versus other classes of antihypertensive medication in the treatment of hypertensive patients with previous stroke and/or coronary artery disease: A systemic review and meta-analysis. American journal of therapeutics. 24(1), 2017, e68-80.
  28. [28]. Chen N, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev. 8, 2010.
  29. [29]. Boutouyrie P, et al. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 55(6), 2010, 1314-22.
  30. [30]. Aursnes I, Osnes JB. Does Atenolol differ from other Beta-Adrenergic Blockers. BMC Clinical Pharmacology. 7, 2007, 4.
  31. [31]. Aursnes I, Osnes JB. Atenolol versus other Beta-Adrenergic Blockers. Journal of the American College of Cardiology. 53(22), 2009.
  32. [32]. Park S, et al. Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure. J AMSocHypertens. 10(10), 2016, 799-810.
  33. [33]. Barrett J, Jeffery R, Rahul B. A systematic review on th efficacy of amolodipine in the treatment of patients with hypertension with concomitantdiabetes mellitus and/or renal dysfunction, when compared to other classes of antihypertensive medication. American journal of therapeutics. 22(5), 2015, 322-341.
  34. [34]. Gradman AH, et.al. Combination therapy in hypertension. Journal of the American Society of Hypertension. 4(2), 2010, p90-98.
  35. [35]. Wlysonge CS, et al. Beta-Blockers for Hypertension. Cochrane Database Syst Rev. 8, 2012.
  36. [36]. Lindholm KH, et al. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lamcet.366(9496), 2005, 1545-53.
  37. [37]. Oparil S, et al. Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials. Drugs. 59, 2000, 25-37.